Up Next

Tweet TWEET

Lpath Ranks Eighth Fastest Growing Biotechnology Company and

Lpath Ranks Eighth Fastest Growing Biotechnology Company and 60th
Overall Among N. America's Fastest Growing Companies in Deloitte's
2012 Technology Fast 500 
Aggressive Growth Attributed to Leadership in Lipid-Targeted
Therapeutics for the Treatment of a Wide Variety of Diseases 
SAN DIEGO, CA -- (Marketwire) -- 12/03/12 --  Lpath, Inc. (NASDAQ:
LPTN), the industry leader in bioactive lipid-targeted therapeutics,
ranked eighth among biotechnology and pharmaceutical companies and
60th overall on the 2012 Technology Fast 500(TM), Deloitte's ranking
of 500 of the fastest growing life sciences, technology, media,
telecommunications and clean technology companies in North America. 
"The 2012 Deloitte Technology Fast 500 winners have demonstrated
remarkable innovation and spectacular growth," said Eric Openshaw,
vice chairman and U.S. technology, media and telecommunications
leader, Deloitte LLP. "Some of the most exciting and useful
developments of the future are being created by the companies on this
list. We congratulate Lpath and all of the winning companies on this
impressive achievement." 
Scott Pancoast, Lpath's president and chief executive officer,
commented: "These rankings are a validation of our unique antibody
drug-discovery engine and our dominating intellectual property. Our
platform produces novel therapeutics that address significant market
opportunities where there is a clear clinical need. The rankings also
reflect our ability to attract financial and strategic partners such
as Pfizer, J&J, Biogen Idec, and Merck-Serono, as well as the NIH and
the Department of Defense." 
Utilizing its ImmuneY2(TM) drug-discovery engine, Lpath has developed
several first-in-class therapeutic antibodies. Each of these
antibodies are designed to target bioactive signaling lipids, such as
S1P (sphingosine-1-phosphate) and LPA (lysophosphatidic acid), that
are involved in the proliferation and spread of neuropathic pain, wet
AMD, inflammatory and auto-immune disorders, cancer, and many other
diseases. 
Lpath is currently moving forward in mid-stage clinical trials with
two anti-S1P antibody formulations. iSONEP(TM) is currently being
evaluated in a Phase 2 clinical trial, called Nexus, which is
evaluating the anti-S1P antibody's safety and efficacy in wet-AMD
patients; ASONEP(TM) will soon be evaluated in a Phase 2a clinical
trial in patients with renal cell carcinoma. 
Lpath entered into an agreement with Pfizer (NYSE: PFE) in 2010 that
provides Pfizer an exclusive option for a worldwide license to
develop and commercialize iSONEP.  
For additional detail on the Technology Fast 500(TM), including
selection and qualifying criteria, visit www.fast500.com. 
About Lpath
 San Diego-based Lpath, Inc., a therapeutic antibody
company, is the category leader in lipid-targeted therapeutics, an
emerging field of medicine that targets bioactive signaling lipids
for treating a wide range of human disease. Lpath's ImmuneY2(TM)
drug-discovery engine has the unique ability to generate therapeutic
antibodies that bind to and inhibit bioactive lipids that contribute
to disease. The company has developed three drug candidates:
iSONEP(TM) is currently in a Phase 2 clinical trial for wet AMD;
ASONEP(TM) will soon begin a Phase 2a clinical trial in Renal Cell
Carcinoma patients; and Lpathomab is a preclinical drug candidate
that holds promise in neuropathic pain, neurotrauma, and other
diseases. For more information, visit www.Lpath.com. 
About Forward-Looking Statements
 The Company cautions you that the
statements included in this press release that are not a description
of historical facts are forward-looking statements. These include
statements regarding: the protection against competition afforded by
issued patents; the eventual commercial viability of the Company's
drug programs; and the Company's ability to complete additional
discovery and development activities for drug candidates utilizing
its proprietary ImmuneY2 drug discovery process. Actual results may
differ materially from those set forth in this press release due to
the risks and uncertainties inherent in the Company's business,
including, without limitation: the outcome of the final analyses of
the data from the Phase 1 clinical trial may vary from the Company's
initial conclusions; the results of any future clinical trials for
iSONEP or ASONEP may not be favorable and the Company may never
receive regulatory approval for iSONEP or ASONEP or any of its drug
candidates; and the Company's may not be able to secure the funds
necessary to support its clinical trial and product development
plans. More detailed information about the Company and the risk
factors that may affect the realization of forward-looking statements
is set forth in the Company's filings with the Securities and
Exchange Commission, including its Annual Report on Form 10-K and its
Quarterly Reports on Form 10-Q filed with the SEC. Such documents may
be read free of charge on the SEC's web site at www.sec.gov. You are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. All
forward-looking statements are qualified in their entirety by this
cautionary statement and the Company undertakes no obligation to
revise or update this press release to reflect events or
circumstances after the date hereof. This caution is made under the
safe harbor provisions of Section 21E of the Private Securities
Litigation Reform Act of 1995. 
Lpath, Inc.
Scott R. Pancoast
President & CEO
(858) 926-3200 
spancoast@Lpath.com 
Lpath Investor Relations
Liolios Group, Inc. 
(949) 574-3860
lptn@liolios.com
Ron Both: ron@liolios.com 
Geoffrey Plank: geoffrey@liolios.com 
 
 
Press spacebar to pause and continue. Press esc to stop.